Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2250 of 3173 entries
View as:

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Phase: N/A Priority: Normal
NCT ID: NCT01353963 Org: User:
Start: 03/31/12 End: 08/31/12 Due: 08/31/13

Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00581555 Org: User:
Start: 10/31/07 End: 11/30/09 Due: 11/30/10

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT03266705 Org: User:
Start: 09/20/17 End: 03/01/18 Due: 03/01/19

Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Phase: N/A Priority: Normal
NCT ID: NCT00562055 Org: User:
Start: 11/30/07 End: - Due: -

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00174343 Org: User:
Start: 11/30/01 End: 09/30/06 Due: 09/30/07

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02928224 Org: User:
Start: 10/13/16 End: 11/10/22 Due: 11/10/23

A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00147485 Org: User:
Start: 12/31/04 End: 08/31/07 Due: 08/31/08

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Phase: N/A Priority: Normal
NCT ID: NCT00684645 Org: User:
Start: 06/30/08 End: 04/30/11 Due: 04/30/12

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Phase: N/A Priority: Normal
NCT ID: NCT04498481 Org: User:
Start: 03/01/18 End: 07/01/18 Due: 07/01/19

Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)

Phase: N/A Priority: Normal
NCT ID: NCT00794118 Org: User:
Start: 06/30/08 End: 04/30/11 Due: 04/30/12

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01909453 Org: User:
Start: 09/12/13 End: 09/03/24 Due: 09/03/25

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Phase: N/A Priority: Normal
NCT ID: NCT01473407 Org: User:
Start: 01/31/12 End: 02/11/14 Due: 02/11/15

Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media

Phase: N/A Priority: Normal
NCT ID: NCT00768534 Org: User:
Start: 10/31/08 End: 10/31/15 Due: 10/31/16

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00460798 Org: User:
Start: 02/28/07 End: 09/30/09 Due: 09/30/10

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Phase: N/A Priority: Normal
NCT ID: NCT01732211 Org: User:
Start: 03/15/13 End: 09/23/13 Due: 09/23/14

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Phase: N/A Priority: Normal
NCT ID: NCT01038297 Org: User:
Start: 12/01/09 End: 07/07/10 Due: 07/07/11

A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State

Phase: N/A Priority: Normal
NCT ID: NCT01563497 Org: User:
Start: 02/29/12 End: 02/29/12 Due: 02/28/13

Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

Phase: N/A Priority: Normal
NCT ID: NCT03548337 Org: User:
Start: 05/31/18 End: 12/20/19 Due: 12/20/20

Prevenar13 Post Market Surveillance

Phase: N/A Priority: Normal
NCT ID: NCT01509105 Org: User:
Start: 09/30/11 End: 01/31/16 Due: 01/31/17

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Phase: N/A Priority: Normal
NCT ID: NCT00394563 Org: User:
Start: 03/31/06 End: 10/31/07 Due: 10/31/08

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Phase: N/A Priority: Normal
NCT ID: NCT04803305 Org: User:
Start: 05/11/21 End: 08/09/22 Due: 08/09/23

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01794364 Org: User:
Start: 01/31/13 End: 03/31/13 Due: 03/31/14

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Phase: N/A Priority: Normal
NCT ID: NCT04767594 Org: User:
Start: 10/27/20 End: 03/30/39 Due: 03/30/40

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05195814 Org: User:
Start: 11/15/21 End: 10/31/23 Due: 10/31/24

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

Phase: N/A Priority: Normal
NCT ID: NCT00784693 Org: User:
Start: 12/18/08 End: 04/05/10 Due: 04/05/11